Drug Information

Drug (ID: DG01700) and It's Reported Resistant Information

• Name: Bevacizumab/Temsirolimus
• Synonyms: Bevacizumab/Temsirolimus
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Colorectal cancer [ICD-11: 2B91]; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Colorectal cancer [ICD-11: 2B91]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Resistant Disease: Colorectal cancer [ICD-11: 2B91.1]
• Molecule Alteration: Missense mutation; p.H1047X (c.3139_3141)
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: The missense mutation p.H1047X (c.3139_3141) in gene PIK3CA cause the resistance of Bevacizumab + Temsirolimus by unusual activation of pro-survival pathway

References

• Ref 1: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitorsMol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7.